|
|
At Myriad Genetics, Jerry Lanchbury led teams that were responsible for major molecular diagnostic innovations across the areas of oncology, urology, rheumatology and neuroscience. Proven track record in molecular genetic discovery, clinical product ideation and translation into high value clinical and companion diagnostics. Discoveries ranged across cancer prognostics, cancer genetic predisposition tests, rheumatoid arthritis disease activity and prognosis and cardiovascular disease risk prediction. Notable field transforming products included myChoice HRD for PARP inhibitors, BracAnalysis CDX for PARP inhibitors, Prolaris, myPlan Lung, myRisk, Riskscore for all ancestries, Vectra and Vectra cardiovascular.
Prior to Myriad Genetics, Lanchbury was a Strateigeic Advisor to Gemini Genomics, Director of Dunhill Medical Research Laboratories, Senior Lecturer in Molecular Immunogenetics, Division of Medicine at United Medical and Dental Schools of Guys and St. Thomas Hospitals, and Deputy Director of Clinical Science Laboratories at United Medical and Dental Schools of Guys and St. Thomas Hospitals.
Jerry earned his BSC (Hons) Biology from Aston University and PhD in Human Population Genetics from Newcastle University.
Prior to Myriad Genetics, Lanchbury was a Strateigeic Advisor to Gemini Genomics, Director of Dunhill Medical Research Laboratories, Senior Lecturer in Molecular Immunogenetics, Division of Medicine at United Medical and Dental Schools of Guys and St. Thomas Hospitals, and Deputy Director of Clinical Science Laboratories at United Medical and Dental Schools of Guys and St. Thomas Hospitals.
Jerry earned his BSC (Hons) Biology from Aston University and PhD in Human Population Genetics from Newcastle University.
